Mellby Gård led a SEK440m funding round in Annoca.

Mellby Gård, a family-owned investment company, led a SEK440m funding round in Annoca, a clinical-stage T-cell immunotherapy company, with participation from AMF Tjänstepension and Ramsbury Invest. “We thank our investors for their strong and continued support as we advance our first TCR-T cell therapy products into the clinic. The team has built a unique discovery platform and in-house manufacturing capability, and we are now excited to see the first products reaching patients with high unmet need,” Reagan Jarvis, Anocca Co-founder and CEO.